Insulin degludec/insulin aspart

Combination insulin medication

Insulin degludec/insulin aspart
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration	Subcutaneous injection
Pregnancy category	C
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Rx-only
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Insulin degludec/insulin aspart is a combination medication used in the management of diabetes mellitus. It is a mixture of two types of insulin: insulin degludec, a long-acting insulin, and insulin aspart, a rapid-acting insulin. This combination is marketed under the brand name Ryzodeg.

Medical uses

Insulin degludec/insulin aspart is indicated for the treatment of type 1 diabetes and type 2 diabetes in adults. It helps to control blood glucose levels by providing both basal and prandial insulin coverage.

Mechanism of action

The combination of insulin degludec and insulin aspart works by mimicking the body's natural pattern of insulin release. Insulin degludec provides a steady, long-lasting insulin level, while insulin aspart offers a rapid onset of action to manage blood sugar spikes after meals.

Administration

The medication is administered via subcutaneous injection. The dosing schedule is typically individualized based on the patient's needs, blood glucose monitoring results, and glycemic control goals.

Side effects

Common side effects include hypoglycemia, allergic reactions, and injection site reactions. Patients should be monitored for signs of low blood sugar and other adverse effects.

See also

• Insulin therapy
• Diabetes management
• Hypoglycemia

External links

• Insulin degludec/insulin aspart on WikiMD